MINOCIN Drug Patent Profile
✉ Email this page to a colleague
When do Minocin patents expire, and what generic alternatives are available?
Minocin is a drug marketed by Bausch, Triax Pharms, Lederle, and Rempex. and is included in five NDAs. There are three patents protecting this drug and one Paragraph IV challenge.
This drug has thirty patent family members in twenty-two countries.
The generic ingredient in MINOCIN is minocycline hydrochloride. There are fifteen drug master file entries for this compound. Thirty-two suppliers are listed for this compound. Additional details are available on the minocycline hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Minocin
A generic version of MINOCIN was approved as minocycline hydrochloride by WATSON LABS on December 30th, 1991.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for MINOCIN?
- What are the global sales for MINOCIN?
- What is Average Wholesale Price for MINOCIN?
Summary for MINOCIN
| International Patents: | 30 |
| US Patents: | 3 |
| Applicants: | 4 |
| NDAs: | 5 |
| Finished Product Suppliers / Packagers: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 148 |
| Clinical Trials: | 44 |
| Patent Applications: | 2,826 |
| Drug Prices: | Drug price information for MINOCIN |
| What excipients (inactive ingredients) are in MINOCIN? | MINOCIN excipients list |
| DailyMed Link: | MINOCIN at DailyMed |
Recent Clinical Trials for MINOCIN
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Baystate Medical Center | Phase 2 |
| Children's Hospital Medical Center, Cincinnati | Phase 1 |
| Sun Yat-sen University | Phase 2 |
Pharmacology for MINOCIN
| Drug Class | Tetracycline-class Drug |
| Physiological Effect | Decreased Prothrombin Activity |
Paragraph IV (Patent) Challenges for MINOCIN
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| MINOCIN | Injection | minocycline hydrochloride | 100 mg/vial | 050444 | 1 | 2020-10-16 |
US Patents and Regulatory Information for MINOCIN
MINOCIN is protected by three US patents.
Patents protecting MINOCIN
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Tetracycline compositions
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING BACTERIAL INFECTIONS
Tetracycline compositions
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING BACTERIAL INFECTIONS
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bausch | MINOCIN | minocycline hydrochloride | CAPSULE;ORAL | 050649-001 | May 31, 1990 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Rempex | MINOCIN | minocycline hydrochloride | INJECTABLE;INJECTION | 050444-001 | Approved Prior to Jan 1, 1982 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Triax Pharms | MINOCIN | minocycline hydrochloride | CAPSULE;ORAL | 050315-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for MINOCIN
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
